Evidence map›Paper›PMID 38004270›Full record

ArticleLife (Basel, Switzerland)2023

Chien-Liang Chao, Han-Peng Kuo, Hsin-Wen Huang, Maw-Yeun Cheng, Hsin-Fan Chao, Shih-Min Lu, Hang-Ching Lin, Chao-Jih Wang, Tsu-Chung Chang, Chi-Rei Wu

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Chien-Liang ChaoSinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan.
Han-Peng KuoSynCore Biotechnology Co., Ltd., Sinphar Group, Yilan 269, Taiwan.
Hsin-Wen HuangSinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan.ORCID 0000-0003-4870-398X
Maw-Yeun ChengSinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan.
Hsin-Fan ChaoSinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan.
Shih-Min LuSinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan.
Hang-Ching LinSinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan.
Chao-Jih WangSinphar Tian-Li Pharmaceutical Co., Ltd., Sinphar Group, Hangzhou 311100, China.
Tsu-Chung ChangDepartment of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan.ORCID 0000-0001-5170-433X
Chi-Rei WuDepartment of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 404, Taiwan.ORCID 0000-0002-7036-5035
National Defense Medical Center · TWChina Medical University · TW

Funding

the Ministry of National Defense MAB-109-055, MND-MAB-110-118
6 · The paper itself

Abstract

The global aging population is expanding at an increasingly rapid pace, with approximately one-fourth of the world's population expected to be composed of elderly individuals by 2050. Aging skin is one of the major characteristics expressed in the elderly. The study comprehensively utilizes both cell and animal experiments to confirm the skin anti-aging effects of

Indexed as

agingcollagenhyaluronic acidlanostane triterpenoidsLipucan®Poria cocos

Identifiers

PMID38004270
PMCPMC10672192
OpenAlexW4388096007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.